Etrolizumab 产品活性：Etrolizumab (rhuMAb Beta7) 是一种肠道选择性抗-β7 整合素单克隆抗体。Etrolizuma b是针对 α4β7 和 αEβ7 整合素的 β7 亚基的特异性靶向活性分子。Etrolizumab 可用于炎症性肠病 (IBD) 的研究。 产品来源： https://www.medchemexpress.cn/etrolizumab.html 研究领域：Cytoskeleton 作用靶点：Integrin In Vitro: Etrolizumab (rhuMAb Beta7) binds the β7 subunit of both α4β7 and αEβ7 integrins with high affinity, with Kd values of 18 nM, 1800 pM, 181 pM, 116 pM, 57 pM, 31.7 pM, and 25.7 pM for Human α4β7, Human αEβ7-293, Mouse α4β7-38C13, Human α4β7-293, Rabbit PBLs, Human PBLs, and Cyno PBLs, respectively. Etrolizumab (RPMI 8866 cells and αEβ7-293 cells) blocks the interaction of α4β7 with its cognate ligands MAdCAM-1 and VCAM-1 with IC50 values of 0.075 and 0.089 nM, respectively, and blocks the interaction between αEβ7 and its ligand E-cadherin with an IC50 value of 3.96 nM. In Vivo: Etrolizumab (rhuMAb Beta7; 5 mg/kg; i.v.; once; normal female BALB/c mice) decreases β7 integrins on T lymphocytes. Etrolizumab (200 µg (100 µL); i.p.; once) inhibits lymphocyte homing in the CD45RBhigh T cell-reconstituted SCID mouse model of colitis. 相关产品：Cilengitide | Cyclo(-RGDfK) | Cucurbitacin B | GLPG0187 | E7820 | MK-0429 | CWHM-12 | Pyrintegrin | Lifitegrast | ATN-161 trifluoroacetate salt | Bexotegrast | Arg-Gly-Asp-Ser | Fibronectin | αvβ1 integrin-IN-1 TFA | Tirofiban | A-205804 | iRGD peptide | GPRP acetate | Carotegrast methyl | Eptifibatide | Vedolizumab | RGD peptide (GRGDNP) (TFA) | RGD | Natalizumab | Tetrac | Leukadherin-1 | BIO5192 | Cyclo(RGDyK) trifluoroacetate 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。